GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Ionis Pharmaceuticals
Ionis Pharmaceuticals is a pioneer in RNA therapeutics. Its stock price is a story of the hopes and risks of the biotech sector. The chart reflects high volatility associated with clinical trial results, regulatory decisions, and partnerships with pharmaceutical giants.
Share prices of companies in the market segment - Dna
Ionis Pharmaceuticals, a pioneer in RNA therapeutics, operates as a single R&D segment, developing new drugs. We refer to this segment as DNA. The chart below shows the overall dynamics of this innovative, yet high-risk, biotech sector.
Broad Market Index - GURU.Markets
Ionis Pharmaceuticals is a pioneer in RNA-targeted therapy, developing drugs to treat a wide range of rare and chronic diseases. Its innovativeness earns it a spot in the GURU.Markets index. The chart below compares its performance with the overall market.
Change in the price of a company, segment, and market as a whole per day
IONS - Daily change in the company's share price Ionis Pharmaceuticals
For Ionis, a pioneer in RNA therapeutics, daily price changes are a measure of its high volatility and response to clinical trial results. The chart of these fluctuations is unspectacular, but they are an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Dna
Ionis Pharmaceuticals, Inc. is a pioneer in RNA therapeutics. This chart highlights the high volatility of the biotech sector. A comparison with IONS, with its extensive but risky pipeline, helps position it as a key bet on this technology.
Daily change in the price of a broad market stock, index - GURU.Markets
Ionis Pharmaceuticals is a leader in the development of antisense RNA therapeutics, a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Ionis's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Ionis Pharmaceuticals
Ionis is a pioneer in antisense-based drug development. Its year-over-year performance reflects both the commercial success of its drugs and investor confidence in its R&D platform, which is focused on new breakthrough drugs, as illustrated by the chart below.
Annual dynamics of market capitalization of the market segment - Dna
Ionis Pharmaceuticals, Inc. is a pioneer in drug development based on antisense RNA technology. Its innovative platform enables the creation of drugs for the treatment of a wide range of diseases. The chart below shows how the market perceives the potential of its unique technology and its partnerships with major pharmaceutical companies.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ionis Pharmaceuticals is a pioneer in the development of RNA-targeted therapies. Its growth is not dependent on economics, but rather is driven by the success of its extensive clinical trial portfolio and partnerships with major pharmaceutical companies.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Ionis Pharmaceuticals
Ionis Pharmaceuticals, a pioneer in antisense therapy, is at the forefront of genetic medicine. Monthly fluctuations on the chart reflect the results of clinical trials of its drugs for rare and chronic diseases, as well as news of partnerships with major pharmaceutical companies.
Monthly dynamics of market capitalization of the market segment - Dna
This chart reflects the dynamics of the biotech sector, where Ionis is a pioneer in RNA therapeutics. Its movements illustrate how the company, with several approved drugs and an extensive R&D pipeline, navigates the highly volatile environment of a sector dependent on clinical trial results.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Ionis Pharmaceuticals is a pioneer in RNA therapeutics, developing drugs for a wide range of diseases. Its performance is driven by news about clinical trials. Against the backdrop of market trends shown in the chart, Ionis shares exist in a scientific world of their own. The success or failure of a single key drug can trigger movements that are incomparable to the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Ionis Pharmaceuticals
Ionis Pharmaceuticals is a leader in the development of RNA-targeted therapies. The company's weekly share price is highly volatile and depends on clinical trial results, partnerships with major pharmaceutical companies, and regulatory decisions.
Weekly dynamics of market capitalization of the market segment - Dna
Ionis Pharmaceuticals is a pioneer in RNA therapeutics. Comparing its weekly performance to the biotech sector can be misleading. This chart shows how news about clinical trials of its numerous drug candidates gives its shares a life of their own, independent of overall industry trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Ionis Pharmaceuticals, a biotech company, exist in a world of their own, far removed from macroeconomic news. Their performance is determined by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can move regardless of the broader market.
Market capitalization of the company, segment and market as a whole
IONS - Market capitalization of the company Ionis Pharmaceuticals
Ionis Pharmaceuticals' market capitalization tells a story about the potential and risks of antisense technology for treating diseases. The company's price chart reflects the roller coaster ride typical of biotech: highs on news of successful trials and lows on failures. It's a visualization of the long and expensive journey from a scientific idea to an FDA-approved drug.
IONS - Share of the company's market capitalization Ionis Pharmaceuticals within the market segment - Dna
Ionis Pharmaceuticals is a pioneer in RNA therapeutics, developing drugs to treat a wide range of diseases. The company's market share reflects the value of its unique technology platform and development pipeline. The chart below shows the weight of this leader in one of the most advanced fields of biotechnology.
Market capitalization of the market segment - Dna
Ionis Pharmaceuticals is a pioneer in RNA therapeutics, developing drugs to treat a wide range of diseases. The chart below shows the overall market capitalization of the DNA technology sector. It reflects investor confidence in the potential of this cutting-edge technology to create new classes of drugs, a field in which Ionis has extensive experience.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart represents the cutting edge of genetic medicine. Ionis Pharmaceuticals is a pioneer in the development of RNA-targeted therapies. Its market cap reflects investors' faith in a new era of drugs capable of "switching off" diseases at the genetic level. This volatile line reflects the risks and enormous hopes of biotech.
Book value capitalization of the company, segment and market as a whole
IONS - Book value capitalization of the company Ionis Pharmaceuticals
Ionis Pharmaceuticals' book value is derived from its intellectual property, such as patents for antisense drug technology, and the capital it has to support expensive clinical trials. This is the scientific foundation. The chart shows how partnerships with major pharmaceutical companies and successful developments have shaped the capital of this RNA therapy pioneer.
IONS - Share of the company's book capitalization Ionis Pharmaceuticals within the market segment - Dna
Ionis Pharmaceuticals is a pioneer in the development of RNA-targeted drugs. Its value lies in its unique scientific platform and patents, not its manufacturing facilities. Its main physical assets are its R&D laboratories. The chart shows a modest share of physical assets, emphasizing that this is a discovery business, not a mass-production one.
Market segment balance sheet capitalization - Dna
Ionis, a pioneer in RNA therapeutics, is a capital-intensive business. This requires advanced R&D centers and in-house manufacturing facilities. The BCap_Seg chart for the biotech sector demonstrates that developing breakthrough technologies requires a robust scientific and manufacturing infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Ionis Pharmaceuticals' assets are not traditional factories, but cutting-edge laboratories and production facilities for creating drugs based on antisense technology. The book value reflects the capital invested in a unique scientific platform. The chart shows how these science-intensive assets compare to traditional pharmaceuticals.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Ionis Pharmaceuticals
Ionis's balance sheet is its laboratories and capital. Its enormous premium reflects the valuation of its innovative antisense technology, which has the potential to treat a wide range of diseases, and its broad pipeline. Its price reflects investors' faith that its scientific platform will deliver breakthrough treatments.
Market to book capitalization ratio in a market segment - Dna
Ionis Pharmaceuticals is a pioneer in the development of RNA-targeted therapies. The company's value is based almost entirely on its unique scientific platform and partnerships with major pharmaceutical companies. The chart reflects the company's high valuation of its intellectual property and the potential of future drugs.
Market to book capitalization ratio for the market as a whole
Ionis Pharmaceuticals is a pioneer in RNA therapeutics. The company's value lies in its unique technological platform and broad pipeline of potential drugs. Its market capitalization is a multiple of its book value, as investors are betting on the future success of its scientific research rather than its current assets.
Debts of the company, segment and market as a whole
IONS - Company debts Ionis Pharmaceuticals
Ionis Pharmaceuticals, a pioneer in RNA therapeutics, uses debt to finance lengthy and expensive clinical trials. Developing next-generation drugs requires significant investment. This chart shows how the company raises capital to advance its extensive pipeline of drugs in various stages of development.
Market segment debts - Dna
Ionis Pharmaceuticals is a pioneer in the development of RNA-targeted therapies. The biotech sector requires massive, long-term, and risky investments in R&D. Its debt policy reflects confidence in the platform's success. This chart shows how Ionis finances its extensive development pipeline, balancing partnerships and capital raising.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Ionis Pharmaceuticals
Ionis Pharmaceuticals is a pioneer in RNA therapeutics, which requires lengthy and expensive clinical trials. This chart shows how the company finances its research platform. The debt level here is an indicator of the confidence of investors and lenders in the potential of its technologies, as well as a proxy for financial risk prior to drug commercialization.
Market segment debt to market segment book capitalization - Dna
Ionis Pharmaceuticals is a pioneer in RNA therapeutics, developing drugs to treat a wide range of diseases. Biotech research is extremely expensive and risky. The chart shows how the company's debt load for R&D funding compares to the overall market capitalization and risks of the pharmaceutical industry.
Debt to book value of all companies in the market
Ionis Pharmaceuticals, a pioneer in RNA therapeutics, finances its expensive R&D, including through debt. This chart allows us to assess the significance of these investments in the future of medicine on an economic scale, comparing the company's debt to the total market capitalization of all sectors.
P/E of the company, segment and market as a whole
P/E - Ionis Pharmaceuticals
Ionis Pharmaceuticals is a leader in the development of antisense drugs—an innovative approach to treating diseases at the genetic level. This chart shows how investors value its scientific platform. The dynamics of this indicator reflect not so much current profits as expectations for clinical trial results and future partnerships with major pharmaceutical companies.
P/E of the market segment - Dna
Ionis Pharmaceuticals is a leader in the development of antisense drugs, a unique technology. This chart shows the average valuation for the biotech sector. It helps understand the premium the market values Ionis for its advanced and broadly applicable scientific platform compared to other biotech companies.
P/E of the market as a whole
Ionis Pharmaceuticals is a pioneer in RNA therapeutics, developing drugs to treat a wide range of diseases. It's a high-risk, but potentially high-reward, scientific business. This chart shows the company's overall risk appetite. For Ionis, as for many biotechs, a positive market environment makes it easier to raise the capital needed for lengthy and expensive clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Ionis Pharmaceuticals
Ionis Pharmaceuticals is a pioneer in RNA-targeted therapy, developing drugs for a wide range of diseases. This chart illustrates market expectations for its extensive clinical development pipeline and partnerships with major pharmaceutical companies, which shape its future value.
%20P%2FE%20Ionis%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Ionis-Pharmaceuticals&v=1772513592250 "Chart of the company's future (projected) P/E Ionis Pharmaceuticals")
Future (projected) P/E of the market segment - Dna
Ionis Pharmaceuticals is a leader in the development of antisense drugs—a technology that enables the treatment of diseases at the genetic level. This chart shows the average profitability expectations in the sector. It helps understand how the market perceives the breadth and potential of Ionis's R&D platform and its numerous partnerships with major pharmaceutical companies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772513592257 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Ionis Pharmaceuticals is a pioneer in the development of antisense drugs, a technology for treating a wide range of diseases at the genetic level. This chart illustrates investors' risk appetite. For a biotech company working on a breakthrough but complex technology, it reflects the market's willingness to fund long-term research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513592286 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Ionis Pharmaceuticals
Ionis Pharmaceuticals is a pioneer in developing RNA-targeted therapies for a wide range of diseases. The financial results shown here are a combination of revenue from approved drugs and payments from joint development partners. The graph illustrates how scientific innovations in genetics are gradually transformed into commercial products.
Profit of companies in the market segment - Dna
Ionis Pharmaceuticals is a leader in antisense therapeutics—a technology that treats diseases at the genetic level. The company has a broad pipeline of drugs in development for various diseases. This chart illustrates how cutting-edge scientific platforms like Ionis's are creating new horizons of profitability in the pharmaceutical industry.
Overall market profit
Ionis Pharmaceuticals is a pioneer in developing RNA therapeutics for a wide range of diseases. The company's success depends on the results of clinical trials and the ability to commercialize innovative drugs. This biotech sector requires long-term investment, which becomes more accessible during periods of strong and profitable economic growth, as this chart illustrates.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Ionis Pharmaceuticals
Ionis Pharmaceuticals is a pioneer in RNA therapeutics, developing drugs for a wide range of diseases. The profit forecast in this chart reflects analysts' expectations from royalties on approved drugs and, more importantly, from clinical trial successes of new candidates. This is a bet on the potential of the entire technology platform.
%20profit%20of%20the%20company%20Ionis%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Ionis-Pharmaceuticals&v=1772513592307 "Graph of future (projected) profit of the company Ionis Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Dna
Ionis Pharmaceuticals is a leader in RNA-targeted therapies, developing drugs for a wide range of diseases. The company has a comprehensive pipeline of drugs at various stages of development. This chart shows the revenue forecast for the DNA technology sector, allowing one to assess the scientific and commercial potential of the Ionis platform relative to the broader biotech industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772513592313 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Ionis Pharmaceuticals is a pioneer in the development of RNA-targeted therapies. As a biotech company, its success depends on clinical trial results and partnerships with major pharmaceutical companies. This chart, reflecting market sentiment, influences the investment climate and company valuations in the innovative healthcare sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513592328 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Ionis Pharmaceuticals
Ionis Pharmaceuticals is a leader in the development of antisense drugs, a new class of medications. This chart shows how investors value the company's revenue, which consists of royalties and partner fees. This high sales valuation reflects the enormous potential of its platform for treating a wide range of diseases.
P/S market segment - Dna
Ionis Pharmaceuticals is a leader in the development of antisense drugs—an innovative approach to treating diseases at the genetic level. The company's revenue comes from royalties from partners and sales of its own drugs. This chart shows how the market values biotech companies, allowing us to assess investor confidence in Ionis's platform and development pipeline.
P/S of the market as a whole
Ionis Pharmaceuticals is a leader in RNA therapeutics, developing drugs for a wide range of diseases. The company has an extensive pipeline and partnerships with major pharmaceutical companies. This chart helps understand how the market evaluates biotech platforms with great potential but also high risks associated with clinical trials.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Ionis Pharmaceuticals
Ionis Pharmaceuticals is a leader in RNA-targeted therapies, developing drugs to treat a wide range of diseases. This chart shows how the market values the company relative to its future sales. It reflects investor expectations for the success of its extensive pipeline and the potential of its entire technology platform.
%20P%2FS%20Ionis%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Ionis-Pharmaceuticals&v=1772513592373 "The graph of the company's future (projected) P/S Ionis Pharmaceuticals")
Future (projected) P/S of the market segment - Dna
Ionis Pharmaceuticals is a leader in RNA-targeted therapies, developing drugs to treat a wide range of diseases, including rare and neurological ones. The company's technology is opening up new approaches to medicine. This chart reflects investor expectations for its innovative platform and future sales compared to other biopharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772513592377 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Ionis Pharmaceuticals is a leader in RNA-targeted therapies. The company's future revenue depends on the success of its extensive clinical development pipeline and partnerships with major pharmaceutical companies. This general expectations chart for IONS is not a direct driver. The company's value is determined by the scientific potential of its platform, not short-term economic trends.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513592380 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Ionis Pharmaceuticals
This chart shows the results of an innovative pharmaceutical company. For Ionis Pharmaceuticals, it reflects revenues consisting of royalties from its successful drug SPINRAZA, as well as payments from large pharmaceutical partners for the joint development of new drugs based on its RNA-targeted technology.
Sales of companies in the market segment - Dna
Ionis Pharmaceuticals is a leader in developing antisense RNA-targeted drugs for the treatment of a wide range of diseases. The company's revenue consists of sales of its own drugs and royalties from partners. This chart shows how success in clinical trials and commercialization of RNA-based therapies impacts the financial performance of Ionis and the entire biotech sector.
Overall market sales
Ionis Pharmaceuticals is a pioneer in RNA therapeutics, developing treatments for a wide range of diseases. The company's success depends on clinical trials and approval of new drugs. Its activities reflect the cutting-edge scientific advances in medicine and exemplify how biotechnology is becoming a powerful growth driver in the healthcare sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Ionis Pharmaceuticals
Ionis Pharmaceuticals is a leader in the development of antisense therapies, an innovative approach to treating diseases at the genetic level. Future sales forecasts depend on the success of clinical trials and the commercialization of its unique drugs. This chart shows analyst expectations for one of the most advanced areas of biotechnology.
%20sales%20of%20the%20company%20Ionis%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Ionis-Pharmaceuticals&v=1772513592402 "Schedule of future (projected) sales of the company Ionis Pharmaceuticals")
Future (projected) sales of companies in the market segment - Dna
Ionis Pharmaceuticals is a pioneer in the development of RNA-based antisense drugs. The outlook for the DNA and RNA therapeutics sector reflects expectations for this cutting-edge field. It reflects the level of confidence among investors and the scientific community in the potential of Ionis' technology to treat a wide range of diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772513592403 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Ionis Pharmaceuticals is a pioneer in developing RNA-targeted therapies for a variety of diseases. The company's success depends on clinical trial results and regulatory approvals, not economic cycles. However, the overall economic situation, as reflected here, impacts the stock market and the availability of capital to fund long-term biotech research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513592407 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Ionis Pharmaceuticals
Ionis Pharmaceuticals, a pioneer in RNA therapeutics, illustrates its partnership-based business model in this diagram. The company's profitability depends not only on direct sales of its own drugs but also on licensing fees and royalties from major pharmaceutical companies with whom it collaborates on the development of new drugs.
Market segment marginality - Dna
Ionis Pharmaceuticals is a leader in the development of antisense drugs, a technology for treating a wide range of diseases. This chart shows the average profitability in the biotech industry. Its unique technology platform and partnerships with major pharmaceutical companies allow Ionis to generate a stable royalty stream and strive for high profitability.
Market marginality as a whole
Ionis Pharmaceuticals is a pioneer in the development of RNA-targeted therapies, a new class of drugs for the treatment of a wide range of diseases. This chart shows the company's overall profit margin. It illustrates Ionis's partnership-based business model. The company's profitability depends on the success of clinical trials and royalties from sales of drugs developed in partnership with major pharmaceutical companies.
Employees in the company, segment and market as a whole
Number of employees in the company Ionis Pharmaceuticals
Ionis Pharmaceuticals is a pioneer in RNA therapeutics, developing drugs for a wide range of diseases. Its core asset is its team of research scientists. The growth illustrated by this chart is directly related to the expansion of its development pipeline and the advancement of drugs through clinical trials in partnership with major pharmaceutical companies.
Share of the company's employees Ionis Pharmaceuticals within the market segment - Dna
Ionis Pharmaceuticals is a pioneer in RNA-targeted therapy, having developed antisense oligonucleotide technology for the treatment of a wide range of diseases. This chart demonstrates its scientific leadership. It reflects the significant number of leading biologists and chemists specializing in this cutting-edge technology that Ionis brings together to create this new class of drugs.
Number of employees in the market segment - Dna
Ionis Pharmaceuticals is a pioneer in RNA-targeted therapy, developing treatments for a wide range of diseases. This chart demonstrates growth in the cutting-edge biotech segment. The company is attracting leading scientists to develop a new class of drugs, reflecting its long-term investment in science that has the potential to transform medicine.
Number of employees in the market as a whole
Ionis Pharmaceuticals is a leader in the development of antisense drugs for the treatment of a wide range of diseases. The company's success depends on the results of clinical trials and partnerships. A stable economic environment, reflected in the chart, is important for attracting investment and securing funding for long-term and risky R&D projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals is a pioneer in the development of antisense technology, a new class of drugs. This chart demonstrates how highly the market values its unique scientific platform. Its high market capitalization per employee demonstrates its team's ability to develop a pipeline of drug candidates and license them to major pharmaceutical companies.
%20of%20the%20company%20Ionis%20Pharmaceuticals%20(IONS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Ionis-Pharmaceuticals-IONS&v=1772513592468 "Chart of market capitalization per employee (in thousands of dollars) of the company Ionis Pharmaceuticals (IONS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Ionis Pharmaceuticals is a pioneer in the development of RNA-targeted therapies. They have created a technological platform for the treatment of a wide range of diseases, often in partnership with large pharmaceutical companies. This chart shows the average industry cost per employee. It helps assess how highly the market values Ionis's scientific platform and its R&D pipeline per scientist and specialist.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772513592471 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Ionis Pharmaceuticals is a pioneer in the development of antisense therapies—a technology for treating diseases at the genetic level. It is an innovative biotech company. This chart shows its high market valuation per employee, as its unique scientific platform could lead to the creation of a whole new class of drugs for previously incurable diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513592474 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals is a leader in RNA therapeutics. They create drugs that can "switch off" disease-causing genes. Their business model is based on R&D and partnerships with major pharmaceutical companies. This chart shows the productivity of their scientific platform. It measures how much revenue (often in the form of royalties or milestone payments) each scientist generates by creating innovative drugs.
%20Chart%20Ionis%20Pharmaceuticals%20(IONS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Ionis-Pharmaceuticals-IONS&v=1772513592475 "Company Profit Per Employee (in thousands of dollars) Chart Ionis Pharmaceuticals (IONS)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Ionis (IONS) is a biotech pioneer and a leader in the antisense R&D platform. This chart shows the benchmark for DNA (Biotech). The average profit per employee in this sector is high. This benchmark reflects the platform R&D model: the sector licenses its technology (IP) to pharma giants, receiving high-margin royalties.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772513592478 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Ionis Pharmaceuticals is a pioneer in RNA therapeutics, developing drugs for a wide range of diseases. The company's business is built on its unique scientific platform. This chart illustrates the biotech company model, where the core value is created by the intellectual work of its scientists, resulting in enormous potential for profit per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513592478 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals is a pioneer in RNA-targeted therapies. This chart demonstrates the effectiveness of its partnership-based business model. Revenue, primarily consisting of royalties and licensing fees, is generated by a small number of employees. This demonstrates how valuable intellectual property can generate revenue with high efficiency.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Ionis-Pharmaceuticals-IONS&v=1772513592480 "Sales chart per company employee Ionis Pharmaceuticals (IONS)")
Sales per employee in the market segment - Dna
Ionis Pharmaceuticals is a leader in the development of RNA-targeted therapies. Their business model is largely based on partnerships with major pharmaceutical companies (Biogen, AstraZeneca). This metric reflects how efficiently their research team generates revenue from licensing fees and royalties. It demonstrates how their R&D platform is monetized compared to other biotech companies.
Sales per employee for the market as a whole
Ionis Pharmaceuticals is a leader in the development of RNA-targeted therapies. Their antisense technology enables the treatment of diseases at the genetic level. Their business model is based on R&D and partnerships with major pharmaceutical companies. This chart shows the revenue (royalties and partnership fees) generated by each researcher. It reflects the effectiveness of their scientific platform.
Short shares by company, segment and market as a whole
Shares shorted by company Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals is a pioneer in RNA therapeutics (antisense drugs). The company has several approved drugs, including Spinraza, and an extensive pipeline. This chart represents bearish bets. Bears may doubt the commercial success of new drugs or expect failures in key clinical trials, a common risk for biotech companies.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Ionis-Pharmaceuticals-IONS&v=1772513592487 "Short Shares Chart for the Company Ionis Pharmaceuticals (IONS)")
Shares shorted by market segment - Dna
Ionis Pharmaceuticals is a leader in developing RNA therapeutics (antisense drugs). It is a high-risk biotech with a long R&D cycle. This chart shows the overall short positions across the biotech sector. The high short interest in the industry reflects general investor skepticism about the sector, possibly due to recent clinical trial failures or funding concerns.
Shares shorted by the overall market
Ionis (IONS) is a pioneer in the development of "antisense" technology, which allows for the treatment of diseases at the genetic level. It is an R&D platform. This chart shows the overall level of fear. When pessimism rises, investors flee biotech, especially those whose profits depend on future scientific breakthroughs and partnerships. Fear of a capital drought is hitting IONS.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals is a pioneer in the development of RNA-targeted therapies. Shares are sensitive to trial news. This chart for IONS can soar above 70 on positive R&D data. Oversold territory (<30) often reflects concerns about research setbacks, competition, or a general flight of investors from the risky biotech sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Ionis-Pharmaceuticals-IONS&v=1772513592510 "RSI 14 indicator chart for the company's stock Ionis Pharmaceuticals (IONS)")
RSI 14 Market Segment - Dna
Ionis Pharmaceuticals (IONS) is a pioneer in antisense RNA technology that "switches off" disease-causing genes. The RSI_14_Seg for "Dna" (biotech) shows the overall sentiment in the sector. The chart helps us understand: is IONS's volatility a reaction to its clinical trials, or is the entire biotech sector overheated (or oversold)?
RSI 14 for the overall market
Ionis Pharmaceuticals is a pioneer in the development of RNA-based therapeutics. This is a high-risk, high-reward biotech. This chart shows the pendulum of market sentiment. For IONS shares, it's crucial to determine whether the market is in a "risk-on" phase (euphoria), when investors are willing to fund innovation, or in a "risk-off" phase (panic), when capital is fleeing speculative ventures.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IONS (Ionis Pharmaceuticals)
Ionis is a pioneer in the development of RNA therapeutics (antisense technology). Their business model is an R&D platform that creates drugs (like Spinraza) and licenses them to pharma giants. This chart shows the average 12-month target from analysts. It reflects their assessment of the value of Ionis's R&D portfolio and future royalties from partners.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IONS-Ionis-Pharmaceuticals&v=1772513592523 "A chart showing analyst consensus forecasts for the expected stock price. IONS (Ionis Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price IONS (Ionis Pharmaceuticals)
Ionis Pharmaceuticals is a pioneer in developing RNA-targeted (antisense) drugs for rare and neurological diseases. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in the success of their extensive pipeline and technology platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IONS-Ionis-Pharmaceuticals&v=1772513592525 "A chart showing the difference between the consensus forecast and the actual stock price. IONS (Ionis Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Dna
Ionis Pharmaceuticals (IONS) is a pioneer in antisense technology, which allows for the "silencing" of disease-causing genes. It has a robust R&D pipeline and partnerships. This chart shows analysts' general expectations for the DNA technology sector, reflecting their belief in the commercial success of this complex platform.
Analysts' consensus forecast for the overall market share price
Ionis Pharmaceuticals (IONS) is a pioneer in antisense (ASO) therapeutics. It is an R&D company with a long history and several products. Market expectations, visible on this chart, influence risk appetite. During a downturn (pessimism), investors are reluctant to fund biotechs, even those with good science, if they have not yet achieved stable profitability.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Ionis Pharmaceuticals
Ionis Pharmaceuticals is a pioneer in antisense therapy, a technology that enables the knockout of disease-causing genes. Their business model is to build an R&D platform and license drugs (like Spinraza) to partners. This chart is a testament to their unique science, reflecting stable royalties from drug sales and confidence in their extensive pipeline.
AKIMA Market Segment Index - Dna
Ionis Pharma is a pioneer in antisense (ASO) technology; a biotech company developing drugs that disable harmful genes (like Alnylam, but with a different technology). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Ionis's unique R&D platform (and its blockbuster Spinraza) differentiate it from the average pharma company?
The AKIM Index for the overall market
Ionis is a pioneer in antisense (ASO) therapeutics, a technology that treats diseases at the RNA level. The company has both its own drugs and partnerships. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative scientific story, rooted in the laws of biotech, compares to overall economic trends.
